Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients

Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural factors. Selexipag is a recently approve...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pulm Circ
Autori principali: Holthaus, Nathan, Prins, Kurt W., Rose, Lauren, Prisco, Sasha, Pritzker, Marc, Thenappan, Thenappan
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2019
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681254/
https://ncbi.nlm.nih.gov/pubmed/31215322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019862167
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi